lenalidomid zentiva 25 mg
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 15 mg
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 10 mg
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 5 mg
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 5 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 25 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 15 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 10 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomide accord
accord healthcare s.l.u. - lenalidomid - viacnásobný myelóm - imunosupresíva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikovaný na liečbu dospelých predtým neliečených pacientov s myelómom je mladších, ktorí nie sú spôsobilí na transplantáciu. lenalidomide dohodou v kombinácii s dexamethasone je indikovaný na liečbu myelómom je mladších dospelých pacientov, ktorí dostali aspoň jeden pred terapia. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
lenalidomide mylan
mylan ireland limited - lenalidomid - viacnásobný myelóm - imunosupresíva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).